Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib) or in advanced clinical trials. We have tested 45 FDA-approved kinase inhibitors in vitro against murine hepatitis virus (MHV) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Puhl, Ana C., Gomes, Giovanni F., Damasceno, Samara, Fritch, Ethan J., Levi, James A., Johnson, Nicole J., Scholle, Frank, Premkumar, Lakshmanane, Hurst, Brett L., LeeMontiel, Felipe, Veras, Flavio P., Batah, Sabrina S., Fabro, Alexandre T., Moorman, Nathaniel J., Yount, Boyd L., Dickmander, Rebekah, Baric, Ralph, Pearce, Kenneth H., Cunha, Fernando Q., Alves-Filho, José C., Cunha, Thiago M., Ekins, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722599/
https://www.ncbi.nlm.nih.gov/pubmed/34981062
http://dx.doi.org/10.1101/2021.12.16.472155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722599/
https://www.ncbi.nlm.nih.gov/pubmed/34981062
http://dx.doi.org/10.1101/2021.12.16.472155

Ejemplares similares